Dry Eye Syndrome: Clinical Trials

10 trials for Dry Eye Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 recruiting, 1 unknown. 10 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 8, Recruiting 1, Unknown 1
Phase 25Completed 4, Unknown 1

Follow Dry Eye Syndrome: new trials by email Literature Review of Dry Eye Syndrome trials Research Report on Dry Eye Syndrome

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
ABBV-319 - Dry Eye Syndrome, Systemic Lupus Erythematosus
Phase 1RecruitingAbbVie362025-08-262026-08-10
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
AGN-242428, AGN-231868, AGN-242428 Vehicle - Dry Eye Disease, Dry Eye Syndrome
Phase 1 / Phase 2CompletedAbbVie2922020-03-042025-05-20
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
SJP-0132, Placebo - Dry Eye Disease, Dry Eye Syndrome
Phase 1 / Phase 2CompletedSenju Pharmaceutical Co., Ltd.892019-10-052023-04-20
Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome
AVX012 Ophthalmic Solution Low dose, AVX012 Ophthalmic Solution High dose, Placebo (vehicle) - Dry Eye Syndrome
Phase 1 / Phase 2UnknownAvizorex Pharma, S.L.1722017-04-032018-10-01
Study of ST266 Eye Drops in Treating Dry Eye
ST266, Refresh Lubricant Eye Drops - Dry Eye Syndrome
Phase 1CompletedNoveome Biotherapeutics, formerly Stemnion302015-03-012019-05-13
Safety and Efficacy of PG101 for Dry Eye Syndrome
PG101 - Dry Eye Syndrome
Phase 1 / Phase 2CompletedRhodes Pharmaceuticals, L.P.722013-12-012014-03-05
Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome
Phase 1 / Phase 2CompletedSylentis, S.A.602012-11-012015-05-25
A Multi-Center Study Subjects With Dry Eye Syndrome
EBI-005-2 - Dry Eye Syndrome
Phase 1CompletedEleven Biotherapeutics742012-11-012013-08-14
Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses
Chitosan-N-acetylcysteine eye drops (concentration of 0.1%), Physiological saline solution - Dry Eye Syndrome
Phase 1CompletedMedical University of Vienna482011-07-012012-12-11
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
DA-6034, Placebo - Dry Eye Syndrome
Phase 1CompletedDong-A ST Co., Ltd.2008-09-012014-10-01

Narrower conditions

Dry Eye Syndromes (10)  ·  Eye Pain (1)  ·  Keratoconjunctivitis Sicca (1)  ·  Lupus Erythematosus, Systemic (1)

Broader conditions

Eye Diseases (10)  ·  Lacrimal Apparatus Diseases (10)  ·  Autoimmune Diseases (1)  ·  Conjunctival Diseases (1)  ·  Conjunctivitis (1)  ·  Connective Tissue Diseases (1)  ·  Corneal Diseases (1)  ·  Eye Manifestations (1)  ·  Immune System Diseases (1)  ·  Keratitis (1)  ·  Keratoconjunctivitis (1)  ·  Neurologic Manifestations (1)  ·  Pain (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Gels (1)  ·  Ophthalmic Solutions (1)  ·  lifitegrast (1)  ·  recoflavone (1)

Sponsors

AbbVie (2)  ·  Avizorex Pharma, S.L. (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Eleven Biotherapeutics (1)  ·  Medical University of Vienna (1)  ·  Noveome Biotherapeutics, formerly Stemnion (1)  ·  Rhodes Pharmaceuticals, L.P. (1)  ·  Senju Pharmaceutical Co., Ltd. (1)  ·  Sylentis, S.A. (1)

Countries

United States (6)  ·  Spain (2)  ·  Austria (1)  ·  France (1)  ·  Netherlands (1)  ·  South Korea (1)

Top investigators

David Steed, MD (1)  ·  Gail Torkildsen, M.D. (1)  ·  Kathy Kelley, OD (1)  ·  Kyung-Sang Yu, M.D., Ph.D., M.B.A (1)  ·  Michael Goldstein, MD (1)  ·  Patrick Tresserras (1)

Results publications

PMID 27893109, PMID 42704415

NIH funding

2016 (1)